Comparative Pharmacology
Head-to-head clinical analysis: METAXALONE versus PARSIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAXALONE versus PARSIDOL.
METAXALONE vs PARSIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metaxalone is a centrally acting muscle relaxant whose exact mechanism is unknown. It is thought to produce skeletal muscle relaxation by depressing the central nervous system (CNS), possibly through general CNS depression or by blocking polysynaptic reflexes in the spinal cord.
Parsidol (ethopropazine) is a phenothiazine derivative that acts as an anticholinergic agent. It inhibits the action of acetylcholine at muscarinic receptors, thereby reducing cholinergic activity in the basal ganglia and restoring the balance between dopaminergic and cholinergic neurotransmission. It also has some dopamine reuptake inhibition and antihistaminic properties.
800 mg orally 3 to 4 times daily
Oral: 2.5-5 mg twice daily, gradually increased to 5-10 mg three times daily; maximum 60 mg/day.
None Documented
None Documented
Clinical Note
moderateMetaxalone + Venlafaxine
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine."
Clinical Note
moderateMetaxalone + Nefazodone
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone."
Clinical Note
moderateMetaxalone + Stiripentol
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Stiripentol."
Clinical Note
moderateMetaxalone + Clomipramine
Terminal elimination half-life is approximately 0.5 to 1.5 hours, reflecting rapid clearance and supporting short-lived clinical effects.
Terminal elimination half-life: 12-24 hours (prolonged in elderly and renal impairment, requiring dose adjustment).
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug, with less than 1% eliminated in feces via biliary excretion.
Renal: 60-70% as unchanged drug; biliary/fecal: 15-20% as metabolites; minor respiratory elimination.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine."